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Introduction
In 2011, 19,164 patients underwent heart valve surgery in 
Japan, and the postoperative early death rate was 3.4 % 
[1]. The number of heart valve surgeries is increasing, and 
the early mortality rate has remained stable for more than 
10 years [2]. Tissue valves are more likely to be implanted 
than mechanical ones in Japan, with 9,832 tissue and 5,452 
mechanical heart valves implanted in 2011. The prolonged 
durability of the tissue valves, an aging population and the 
expansion of plastic surgery techniques have all decreased 
mechanical valve use. However, mechanical valves appear 
to be a better option for some patients. We choose a 
mechanical valve for young adults and patients with end-
stage renal disease because of the more rapid onset of 
structural dysfunction of tissue valves [3].
Many patients now survive for many years after valve 
implantation, with a reported 10-year survival rate of at 
least 60 % [4–7]. However, unfavorable complications can 
occur after valve surgery. We herein review and discuss 
mechanical prosthetic valve-related complications.
All valve‑related complications
Edmunds et al. [8] designed the guidelines for reporting out-
comes after prosthetic valve replacement, and many articles 
have been published based on these guidelines. The authors 
stated that the valve-related complications include throm-
boembolisms, bleeding complications and prosthetic valve 
endocarditis, followed by structural and nonstructural pros-
thetic valve dysfunctions. Our review of studies published 
after 2000 revealed a rate of valve-related complications of 
0.7–3.5 % per patient-year [2, 8–14]. The occurrence rates of 
individual complications and references are shown in Table 1.
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Thromboembolism and bleeding complications
Thromboembolisms, such as cerebral infarction and pros-
thetic valve thrombosis, and bleeding complications might 
be related to the use of warfarin anticoagulation therapy. 
Other reasons include intrinsic coagulation factors, intes-
tinal lesions, atrial enlargement, arrhythmias such as atrial 
fibrillation and other causes. A preoperative history of cer-
ebrovascular events is also a risk factor for thromboembolic 
or bleeding complications [5, 15, 16]. Thromboembolisms 
occur at a rate of approximately 1 % per patient-year, and 
bleeding complications at almost 0.5 % per patient-year.
The 2014 American Heart Association/American Col-
lege of Cardiology guidelines for the management of 
patients with valvular heart disease state that an inter-
national normalized ratio (INR) of 2.5 is recommended 
in patients with a mechanical valve at the aortic position, 
and an INR of 3.0 should be obtained for those with a 
valve implanted at the mitral position [17]. Therapy with 
75–100 mg aspirin daily is also recommended. Some 
authors recommend an INR of 2.6–3.0 for aortic valve 
replacement patients and 3.0–3.5 for mitral valve replace-
ment patients [9, 10]. The Japanese guideline published 
in 2012, however, recommended a slightly lower INR 
between 2.0 and 3.0 [18]. Our present INR target value is 
between 1.8 and 3.0 for all patients, with additional dipy-
ridamole or aspirin administration [4]. For patients with 
atrial fibrillation and young patients, our criterion is based 
on the same recommendation, but for older patients with 
risk factors for cerebral bleeding, our target INR is below 
this recommendation.
A thrombosed prosthetic valve is an uncommon com-
plication, but it is associated with high mortality and mor-
bidity rates. In a literature survey of the clinical outcomes 
of patients with obstructive thrombosed prosthetic heart 
valves, Huang et al. [19] concluded that thrombolytic ther-
apy was easier than surgery, with a recurrence rate of 13 %, 
while surgery was necessary in the 30 % of cases with 
failure of thrombolytic therapy, and was associated with a 
mortality rate of at least 12 %.
Endocarditis
Prosthetic valve endocarditis requires complicated surgical 
procedures [10, 20] and sometimes leads to lethal clinical 
results, particularly in early-onset patients [21–25]. The 
occurrence rate of endocarditis is approximately 0.5 % per 
patient-year. In 1996, Lytle et al. [21] showed that 13 % 
of 146 patients had in-hospital deaths, and in 2014, Gru-
bitzsch et al. [22] showed that the surgical mortality was 
12.8 % among 149 consecutive patients with prosthetic 
valve endocarditis. Therefore, the surgical risk of prosthetic 
heart valve endocarditis remains high, and Staphylococcal 
species are the most common causative organisms [20, 21].
The postoperative survival in endocarditis patients is 
poor. Lytle and colleagues indicated that additional surgery 
was required in 19 of their patients, with a 60 % survival 
rate at 10 years among the 127 hospital survivors [2, 4]. 
Grubitzsch et al. [22] recorded 69 early and late complica-
tions, including 35 deaths, 23 recurrences and 11 reopera-
tions among 121 patients with a mean follow-up of 4 years.
Structural dysfunction
Structural dysfunction in first-generation and initial 
mechanical valves, such as the Starr-Edwards ball and 
Björk-Shiley valves, have been reported, although the 
long-term clinical results of both valves have been excel-
lent [26–32]. The main causes of Starr-Edwards ball valve 
dysfunction have been ball fracture and cloth wear and tear, 
leading to valve regurgitation [33, 34]. Björk-Shiley valve 
dysfunctions include leaflet dislodging and fracture.
These rare complications are typically observed more 
than three or four decades after implantation. Gunn et al. 
[31] concluded that the Björk-Shiley valve conferred 
excellent 30-year survival, was associated with three strut 
fractures during long-term follow-up, with a freedom from 
reoperation rate of 91 % at 30 years. Harrison et al. [32] 
discussed 663 catastrophic failures of the valve among 
approximately 86,000 patients, and we reported a case of 
extraction of a worn Björk-Shiley prosthetic valve after 
39 years because of the potential risk of structural valve 
dysfunction [35, 36]. The implanted valve was function-
ing well in our case, but we identified the worn disc during 
aortic surgery for an acute aortic dissection. Björk pointed 
out the potential risk of disc wear and fracture, and the 
Björk-Shiley valve may be changed to pyrolytic carbon 
discs [37].
As mentioned above, the structural dysfunc-
tion of mechanical valves has been largely resolved, 
Table 1  The occurrence rates of complications and references
All valve-related complications Thromboembolism Bleeding Endocarditis Nonstructural dysfunction
% per patient-year 0.7–3.5 Approximately 1.0 <0.5 <0.5 0.4–1.2
References [2, 8–14] [5, 9, 10, 15–19] [5, 15, 16] [10, 21–25] [9, 39–57]
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including leaflet dislodging and disc fracture and the cur-
rent mechanical valves show an extremely low occurrence 
rate of structural valve dysfunction. Structural dysfunc-
tion among major commercially available mechanical 
valves cannot be recognized, even in children [4–7]. Cur-
rently, structural dysfunction remains an issue with tissue 
valves.
In 2008, Cianciulli et al. [38] reported a case of struc-
tural dysfunction in a mechanical prosthetic valve made by 
Tri-technologies Inc., which is a made-to order manufac-
turer that produces vales for sale to private customers. This 
case is a specific example, and not the norm.
Nonstructural dysfunction
Nonstructural valve dysfunction includes paravalvular 
leaks without apparent endocarditis, cusp entrapment by a 
pannus or other causes. Clinically important hemolytic ane-
mia can occur with a lower incidence than these complica-
tions [39].
Before the publication of guidelines for a linearized rate 
for reporting outcomes after prosthetic valve replacement, 
investigators did not report nonstructural dysfunction sys-
tematically. The nonstructural dysfunction rate reported by 
Edmunds and colleagues was 0.4–1.2 % per patient-year 
among recent mechanical heart valves [40–43].
Paravalvular leaks without apparent endocarditis and 
pannus formation often lead to reoperation, and are caused 
by technical errors, latent prosthetic endocarditis or annular 
calcification. A minor leak might be subclinical in the aortic 
position, but hemolysis caused by the leak can lead to reop-
eration in the mitral position. Akins et al. [44] reported the 
clinical results of 136 consecutive patients with paravalvu-
lar leaks, and primarily repaired or replaced the implanted 
valves. We reported a case that presented with hemolysis 
5 years after a third mitral valve operation [45]. The intra-
operative findings revealed severe calcification around the 
regurgitant orifice, and we successfully repaired the valve 
primarily. We inferred that the hard calcification and the 
prosthetic valve ring wore the tissue around the prosthesis. 
Technical errors should be overcome, and improved histo-
compatibility of the suture ring of the mechanical valves 
may also help avoid this complication.
Pannus formation might prevent a leaflet from function-
ing well, and the presence of a pannus on the outflow of the 
left ventricle below a mechanical valve could narrow the 
outflow orifice, causing stenosis. This complication occurs 
mainly after long procedures. We reported a case with a 
pannus, in which the pannus was resected using rotatable 
tilting disc prosthesis, resulting in successful preserva-
tion of the intact prosthesis [46]. We also experienced four 
other reoperation cases due to pannus formation [47, 48]. 
The earliest case received reoperation at 97 months, and the 
other three cases were treated between 20 and 39 years after 
the initial operations. Oh et al. [49] reported a large amount 
of pannus ingrowth in 33 aortic valve replacement patients 
with an increased mean pressure gradient. The mean inter-
val from the previous operation was 16.7 ± 4.3 years, and 
the authors showed that the most common etiology for the 
previous surgery was rheumatic valve disease. Ellensen 
et al. [50] also reported a large series of 27 cases, and 
showed that females and younger patients had a higher risk 
of pannus formation. Al-Alao et al. [51] reported a rare 
case with pannus formation 3 months after surgery. Certain 
intrinsic factors might contribute to pannus formation, and 
manufacturers have been changing their designs and suture 
ring fabric compositions to prevent a pannus from develop-
ing. The results of these changes will take several decades 
to become evident.
In addition, diagnosing pannus formation is not easy. 
The clinical signs of implanted valve dysfunction, such as 
stenosis, might indicate certain diagnostic procedures, and 
an echocardiogram is the key to detect valve dysfunction. 
However, Xu et al. [52] showed that fluoroscopic exami-
nation was useful to reveal a radio-opaque ring within the 
implanted valve orifice, and Teshima et al. [53] studied the 
effectiveness of multidetector-row-computed tomography 
to demonstrate pannus overgrowth on the inflow aspect of 
the prosthetic valve.
Some authors found an annular valve suture interfering 
with the normal closure mechanism of a prosthetic leaflet, 
causing valve dysfunction [54, 55]. The normal prosthetic 
valve function was restored after removing the suture 
material. Apparent hemolysis without a paravalvular leak 
has been rarely reported [9, 56, 57]. Borman et al. [57] 
showed that simultaneous aortic and mitral valve replace-
ment caused relatively increased hemolysis compared 
with single valve replacements, and indicated that all of 
six instances treated at their institution did not require 
reoperation.
Conclusions
Valve-related complications after heart valve replacement 
with mechanical valves occur at acceptable rates. The 
structural dysfunction has been largely overcome; how-
ever, prosthetic valve endocarditis may still result in death. 
Thromboembolic and hemorrhagic events related to antico-
agulant therapy should be considered during life-long fol-
low-up. Nonstructural prosthetic valve dysfunctions, such 
as paravalvular leaks and pannus ingrowth, are also issues 
that need to be resolved.
1208 Surg Today (2015) 45:1205–1209
1 3
Conflict of interest The author serves as a consultant for Terumo 
Co.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. Amano J, Kuwano H, Yokomise H. Thoracic and cardiovascular 
surgery in Japan during 2011. Annual report by The Japanese 
Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 
2013;61:578–607.
 2. Taniguchi S, Hashizume K, Ariyoshi T, Hisara Y, Tanigawa K, 
Miura T, Odate T, Matsukuma S, Nakaji S, Eishi K. Twelve years 
of experience with the ATS mechanical heart valve prostheses. 
Gen Thorac Cardiovasc Surg. 2012;61:561–8.
 3. Misawa Y. Heart valve replacement for patients with end-
stage renal disease in Japan. Ann Thorac Cardiovasc Surg. 
2010;16:4–8.
 4. Misawa Y, Saito T, Konishi H, Ohki S, Kaminishi Y, Sakano Y, 
Morita H, Aizawa K. Clinical experience with the Bicarbon heart 
valve prosthesis. J Cardiothorac Surg. 2007;25(2):8.
 5. Misawa Y, Fuse K, Saito T, Konishi H, Oki S. Fourteen year 
experience of the Omnicarbon prosthetic heart valve. ASAIO J. 
2001;47:677–83.
 6. Aoyagi S, Oryoji A, Nishi Y, Tanaka K, Kosuga K, Oishi K. 
Long-term results of valve replacement with the St. Jude Medical 
valve. J Thorac Cardiovasc Surg. 1994;108:1021–9.
 7. Shanmugam G, MacArthur K, Pollock J. Mechanical aortic valve 
replacement: long-term outcomes in children. J Heart Valve Dis. 
2005;14:166–71.
 8. Edmunds LH, Clark RE, Cohn LH, Grunkemeier GL, Miller DC, 
Weisel RD. Guideline for reporting morbidity and mortality after 
cardiac valvular operations. Ann Thorac Surg. 1996;62:932–5.
 9. Azamoush K, Laborde F, de Riberolles C. The Sorin Bicarbon 
over 15 years clinical outcomes: multicenter experience in 1704 
patients. Eur J Cardiovasc Surg. 2010;38:759–66.
 10. Van Nooten G, Bové T, Van Belleghem Y, François K, Caes F, 
Vandenplas G, De Pauw M, Taeymans Y. Twenty-year single-
center experience with the Medtronic open pivot mechanical 
heart valve. Ann Thorac Surg. 2014;97:1306–13.
 11. Sezai A, Hata M, Niino T, Yoshitake I, Kasamaki Y, Hiray-
ama A, Minami K. Fifteen years of experience with ATS 
mechanical heart valve prostheses. J Thorac Cardiovasc Surg. 
2010;139:1494–500.
 12. Baykut D, Grize L, Schindler C, Keil AS, Bernet F, Zerkowski 
HR. Eleven-year single-center experience with the ATS open 
pivot bileaflet heart valve. Ann Thorac Surg. 2006;82:847–52.
 13. Spillopolos K, Haschemi A, Parasiris P, Kemkes BM. Sorin 
Bicarbon bileaflet valve: a 9.8-year experience. Clinical per-
formance of the prosthesis after heart valve replacement in 587 
patients. Inteact Cardiovasc Thorac Surg. 2009;8:252–9.
 14. Borman JB, De Riberolles C. Sorin Bicarbon bileaflet valve: a 
10-year experience. Eur J Cardiothorac Surg. 2003;23:86–92.
 15. Labaf A, Grzymala-Lubanski B, Stagmo M, Lövdahl S, Wieloch 
M, Själander A, Svensson PJ. Thromboembolism, major bleeding 
and mortality in patients with mechanical heart valve-a popula-
tion-based cohort study. Thromb Res. 2014;134:354–9.
 16. Bourguignon T, Bergöend E, Mirza A, Ayegnon G, Neville 
P, Aupart MR, Marchand M. Risk factors for valve-related 
complications after mechanical heart valve replacement in 
505 patients with long-term follow up. J Heart Valve Dis. 
2011;20:673–80.
 17. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 
III, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P. 2014 
AHA/ACC guideline for the management of patients with valvu-
lar heart disease: executive summary: a report of the American 
College of Cardiology/American Heart Association task force on 
practice guidelines. J Am Coll Cardiol. 2014;63:2438–88.
 18. Ookita Y, Okada Y, Otsuji Y, Komeda M, Nakatani S, Matsuzaki 
M, Yoshida K (2012) Guidelines for surgical and interventional 
treatment of vascular heart disease (JCS). http://www.j-circ.or.jp/
guideline/pdf/JCS2012_ookita_d.pdf. Accessed 20 Oct 2014.
 19. Huang G, Schaff HV, Sundt TM, Rashimtoola SH. Treatment of 
obstructive thrombosed prosthetic heart valve. J Am Coll Cardiol. 
2013;62:1731–6.
 20. Ramlawi B, White LE, Santora RJ, Reardon MJ. Recurrent pros-
thetic valve endocarditis with aortic-ventricular disruption: a sur-
gical challenge. J Heart Valve Dis. 2013;22:126–33.
 21. Lytle BW, Priest BP, Taylor PC, Loop FD, Sapp SK, Stewart 
RW, McCarthy PM, Muehrcke D, Cosgrove DM. Surgical treat-
ment of prosthetic valve endocarditis. J Thorac Cardiovasc Surg. 
1996;111:198–207.
 22. Grubitzsch H, Schaefer A, Melzer C, Wernecke KD, Gabbieri D, 
Konertz W. Outcome after surgery for prosthetic valve endocardi-
tis and the impact of preoperative treatment. J Thorac Cardiovasc 
Surg. 2014. doi:10.1016/j.jtcvs.2014.05.025.
 23. Lalani T, Chu VH, Park LP, Cecchi E, Corey GR, Durante-Man-
goni E, Fowler VG, Gordon D, Grossi P, Hannan M, Hoen B, 
Muñoz P, Rizk H, Kanj SS, Selton-Suty C, Sexton DJ, Spelman 
D, Ravasio V, Tripodi MF, Wang A. In-hospital and 1-year mor-
tality in patients undergoing early surgery for prosthetic valve 
endocarditis. JAMA Intern Med. 2013;173:1495–504.
 24. Nonaka M, Kusuhara T, An K, Nakatsuka D, Sekine Y, Iwakura 
A, Yamanaka K. Comparison between early and late prosthetic 
valve endocarditis: clinical characteristics and outcomes. J Heart 
Valve Dis. 2013;22:567–74.
 25. Chirillo F, Scotton P, Rocco F, Rigoli R, Pedrocco A, Martire P, 
Daniotti A, Minniti G, Polesel E, Olivari Z. Management strate-
gies and outcome for prosthetic valve endocarditis. Am J Cardiol. 
2013;112:1177–81.
 26. Björk VO. Disc wear in the Björk-Shiley tilting disc valve. 
Experiment and clinical observation. Scand J Thorac Cardiovasc 
Surg. 1971;5:87–91.
 27. Björk VO. The pyrolytic carbon occluder for the Björk-Shi-
ley disc valve prosthesis. Scand J Thorac Cardiovasc Surg. 
1972;6:109–13.
 28. Larmi TK, Kärkölä P. Shrinkage and degradation of Del-
rin occlude in the tilting disc valve. J Thorac Cardiovasc Surg. 
1974;68:66–9.
 29. Masumoto H, Shimamoto M, Yamazaki F, Nakai M, Fujita S, 
Miura Y. A case report of valve dysfunction. A case report of 
valve dysfunction associated with abrasion of Delrin disk used in 
early Björk-Shiley mitral valves requiring resurgery. Ann Thorac 
Cardiovasc Surg. 2009;15:126–8.
 30. Motoki T, Matsueda T, Kurushima A, Otani T, Fukumura Y. Pros-
thetic valve dysfunction resulting from a Björk-Shiley Delrin 
disc fracture in the mitral position: a case report. Tokushima Red 
Cross Hosp Med J. 2013;18:36–9.
 31. Gunn JM, Malmberg M, Vähäsilta T, Lahti AL, Kuttila KT. 
Thirty-year results after implantation of the Björk-Shiley 
convexo-concave heart valve prosthesis. Ann Thorac Surg. 
2014;97:552–6.
 32. Harrison DC, Ibrahim MA, Weyman AE, Kuller LH, Blot WJ, 
Miller DE. The Björk-Shiley convexo-concave heart valve 
1209Surg Today (2015) 45:1205–1209 
1 3
experience from the perspective of the supervisory panel. Am J 
Cardiol. 2013;112:1921–31.
 33. Shiono M, Sezai Y, Sezai A, Hata M, Iida M, Negishi N. Long-
term results of the cloth-covered Starr-Edwards ball valve. Ann 
Thorac Surg. 2005;80:204–9.
 34. Mazzucco A, Luciani GB, Pessotto R, Piccin C, Faggian G, Chio-
minto B. Ball fracture with the 6120-model Starr-Edwards mitral 
valve prosthesis occurring late after implantation. J Heart Valve 
Dis. 1993;2:245–7.
 35. Komi M, Sugaya A, Akutsu H, Sato H, Kaminishi Y, Misawa Y. A 
worn Björk-Shiley prosthetic valve without dysfunction observed 
during ascending aortic replacement. Clinical Case Reports. 
2014;2:180–2.
 36. Björk VO. Disc wear in the Björk-Shiley tilting disc valve. 
Experiment and clinical observation. Scand J Thorac Cardiovasc 
Surg. 1971;5:87–91.
 37. Björk VO. The pyrolytic carbon occluder for the Björk-Shi-
ley disc valve prosthesis. Scand J Thorac Cardiovasc Surg. 
1972;6:109–13.
 38. Cianciulli TF, Lax JA, Saccheri MC, Guidoin R, Salvado CM, 
Fernández AJ, Prezioso HA. Retrieval of a leaflet escaped in a 
Tri-technologies bileaflet mechanical prosthetic valve. Eur J 
Echocardiogr. 2008;9:65–8.
 39. Hurle A, Abad C, Feijoo J, Ray V, Ponce G. Long-term clini-
cal performance of Sorin tilting-disc mechanical prostheses 
in the mitral and aortic position. J Cardiovasc Surg (Torino). 
1997;38:507–12.
 40. Cellento M, Filaferro L, Milano AD, Anastasio G, Ferrari G, Bor-
tolotti U. Single center experience with the Sorin Bicarbon pros-
thesis: a 17-year clinical follow-up. J Thorac Cardiovasc Surg. 
2013. doi:10.1016/j.jtcvs.2013.11.015.
 41. Nishida T, Sonoda H, Oishi Y, Tanoue Y, Nakashima A, Shiokawa 
Y, Tominaga R. Single-institution, 22-year, follow-up of 786 Car-
boMedics mechanical valves used for both primary surgery and 
reoperation. J Thorac Cardiovasc Surg. 2014;147:1493–8.
 42. Rezulli A, Ismeno G, Bellitti R, Casale D, Festa M, Nappi GA, 
Cotrufo M. Long-term results of heart valve replacement with 
bileaflet prostheses. J Cardiovasc Surg (Torino). 1997;38:241–7.
 43. Bernet FH, Baykut D, Grize L, Zerkowski HR. Single-center 
outcome analysis of 1,161 patients with St. Jude medical and 
ATS open pivot mechanical heart valves. J Heart Valve Dis. 
2007;16:151–8.
 44. Akins CW, Bitondo JM, Hilgenberg AD, Vlahakes GJ, Madsen 
JC, MacGillivray TE. Early and late results of the surgical correc-
tion of cardiac prosthetic paravalvular leaks. J Heart Valve Dis. 
2005;14:792–9.
 45. Aizawa K, Tateishi A, Sakano Y, Kaminishi Y, Ohki S, Saito T, 
Konishi H, Kawada M, Misawa Y. Repair of paravalvular leak after 
third mitral valve replacement. Kyobu Geka. 2007;60:903–5.
 46. Misawa Y, Fuse K, Kato M. Pannus resection through the tilting 
disc prosthesis: successful treatment preserving the prosthesis. 
Artif Org. 1997;21:1301–2.
 47. Misawa Y, Saito T, Konishi H, Oki S, Kaminishi Y, Aizawa K, 
Takahashi H, Kamisawa O, Kato M, Fuse K. When and how 
does mechanical prosthetic heart valve dysfunction appear? Jpn J 
Thorac Cardiovasc Surg. 2003;51:355–60.
 48. Misawa S, Aizawa K, Kaminishi Y, Muraoka A, Misawa Y. Starr-
Edwards valves at the aortic and mitral positions implanted for 39 
years. Gen Thorac Cardiovasc Surg. 2011;59:433–5.
 49. Oh SJ, Park S, Kim JS, Kim KH, Kim KB, Ahn H. Reop-
eration for non-structural valvular dysfunction caused by pan-
nus ingrowth in aortic valve prosthesis. J Heart Valve Dis. 
2013;22:591–8.
 50. Ellensen VS, Andersen KS, Vitale N, Davidsen ES, Segadal L, 
Haaverstad R. Acute obstruction by pannus in patients with aortic 
medtronic-hall valves: 30 years of experience. Ann Thorac Surg. 
2013;96:2123–8.
 51. Al-Alao B, Simonjul U, Heron B, Parissis H. Rapid pannus for-
mation after few months of obstructing aortic mechanical pros-
thesis. Gen Thorac Cardiovasc Surg 2013 Sep 25. Epub ahead of 
print.
 52. Xu B, La Gerche A, Nixon I, Maclsaac A. Fluoloscopic ring of 
pannus within a mechanical mitral valve: a novel sign of calci-
fied pannus infiltration. Heart Lung Circ. 2014. doi:10.1016/j.
hlc.2014.06.002.
 53. Teshima H, Aoyagi S, Hayashida N, Shojima T, Takagi K, Ari-
naga K, Yoshikawa K. Dysfunction of an ATS valve in the aor-
tic position: the first reported case caused by pannus formation. J 
Artif Organs. 2005;8:270–3.
 54. Kidher ES, Perera R, Rao C, Rehman SM, Sutaria N, Atha-
nasiou T. A rare case of suture material obstructing the closure 
mechanism of a prosthetic aortic valve: a case report. Cases J. 
2009;2(2):9126. doi:10.1186/1757-1626-2-9126.
 55. Ozakan M, Astarcioglu MA, Karakoyun S, Balkanay M. Extrin-
sic mechanism obstructing the opening of a prosthetic mitral 
valve: an unusual case of suture entrapment. Echocardiography. 
2012;29:E28–9.
 56. Nakano K, Koyanagi H, Hashimoto A, Kitamura M, Endo 
M, Nagashima M, Tokunaga H. Twelve years’ experience 
with the St. Jude Medical valve prosthesis. Ann Thorac Surg. 
1994;57:697–703.
 57. Borman JB, De Riberolles C. Sorin Bicarbon bileaflet valve: a 
10-year experience. Eur J Cardiothorac Surg. 2003;23:86–92.
